Originally published by our sister publication Pharmacy Practice News
The future of pulmonary medicine is rapidly evolving, with biologic therapies hitting multiple targets in asthma and/or chronic obstructive pulmonary disease (COPD), said experts at ASHP Pharmacy Futures 2024, in Portland, Ore.
In asthma, currently available biologics target cytokines associated with type 2 (T2) inflammation, the phenotype found in most patients with severe asthma, said Alison Lobkovich, PharmD, a